Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

390 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.
Burkhardt O, Derendorf H, Welte T. Burkhardt O, et al. Expert Opin Pharmacother. 2007 Feb;8(2):237-56. doi: 10.1517/14656566.8.2.237. Expert Opin Pharmacother. 2007. PMID: 17257093 Review.
Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis.
Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H. Burkhardt O, et al. J Antimicrob Chemother. 2006 Sep;58(3):632-6. doi: 10.1093/jac/dkl284. Epub 2006 Jul 12. J Antimicrob Chemother. 2006. PMID: 16840426 Clinical Trial.
Ertapenem concentrations in plasma reached a maximum (C(max)) of 103.3 +/- 26.3 mg/L, a terminal elimination half-life (t(1/2)) of 3.8 +/- 0.6 h and an AUC(0-infinity) of 359.7 +/- 66.5 mg.h/L. ...AUC(0-infinity) values for both muscle and adipose tissue were lower …
Ertapenem concentrations in plasma reached a maximum (C(max)) of 103.3 +/- 26.3 mg/L, a terminal elimination half-life (t(1/2)) of 3.8 +/- 0 …
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Burkhardt O, et al. J Antimicrob Chemother. 2006 Oct;58(4):822-9. doi: 10.1093/jac/dkl328. Epub 2006 Aug 2. J Antimicrob Chemother. 2006. PMID: 16885180 Clinical Trial.
PATIENTS AND METHODS: In a single-centre, open, randomized, controlled, non-blinded study 33 adult CF patients (20 females, 19-37 years) were treated with intravenous tobramycin (10 mg/kg/day) for 14 days given either as single dose once a day (Q24; 17 patients) or divided into t …
PATIENTS AND METHODS: In a single-centre, open, randomized, controlled, non-blinded study 33 adult CF patients (20 females, 19-37 years) wer …
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Buck C, et al. Int J Antimicrob Agents. 2005 Jan;25(1):62-7. doi: 10.1016/j.ijantimicag.2004.08.012. Int J Antimicrob Agents. 2005. PMID: 15620828 Clinical Trial.
In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose....
In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing …
Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis.
Burkhardt O, Derendorf H, Jäger D, Kumar V, Madabushi R, Röhl K, Barth J. Burkhardt O, et al. Scand J Infect Dis. 2006;38(10):904-8. doi: 10.1080/00365540600664076. Scand J Infect Dis. 2006. PMID: 17008236
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.
Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T. Burkhardt O, et al. J Antimicrob Chemother. 2007 Feb;59(2):277-84. doi: 10.1093/jac/dkl485. Epub 2006 Dec 21. J Antimicrob Chemother. 2007. PMID: 17185298
Blood and urine samples were collected before and at different time-points up to 24 h after medication on day 1. Concentrations of ertapenem in plasma were determined with a validated HPLC method. ...The enhanced V(z) (17 vs. 8 L) and CL(TOT) (43 vs. 20 mL/min) with result …
Blood and urine samples were collected before and at different time-points up to 24 h after medication on day 1. Concentrations of er …
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.
Burkhardt O, Majcher-Peszynska J, Borner K, Mundkowski R, Drewelow B, Derendorf H, Welte T. Burkhardt O, et al. J Clin Pharmacol. 2005 Jun;45(6):659-65. doi: 10.1177/0091270005276117. J Clin Pharmacol. 2005. PMID: 15901747 Clinical Trial.
In plasma, ertapenem exhibited a Cmax of 94.7 +/- 23.3 mg/L and an AUC(0-last) of 501.1 +/- 266.3 mg x h/L. These results, combined with the reported (MIC)90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP....
In plasma, ertapenem exhibited a Cmax of 94.7 +/- 23.3 mg/L and an AUC(0-last) of 501.1 +/- 266.3 mg x h/L. These results, combined w …
Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.
Sy SK, Zhuang L, Derendorf H. Sy SK, et al. Expert Opin Drug Metab Toxicol. 2016;12(1):93-114. doi: 10.1517/17425255.2016.1123250. Epub 2015 Dec 14. Expert Opin Drug Metab Toxicol. 2016. PMID: 26652832 Review.
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
Gloede J, Scheerans C, Derendorf H, Kloft C. Gloede J, et al. J Antimicrob Chemother. 2010 Feb;65(2):186-201. doi: 10.1093/jac/dkp434. Epub 2009 Dec 21. J Antimicrob Chemother. 2010. PMID: 20026612 Review.
PK/PD: new insights for antibacterial and antiviral applications.
Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. Schmidt S, et al. Curr Opin Pharmacol. 2008 Oct;8(5):549-56. doi: 10.1016/j.coph.2008.06.010. Epub 2008 Jul 30. Curr Opin Pharmacol. 2008. PMID: 18625339 Review.
390 results
Jump to page
Feedback